phase i/ii study of a novel bet inhibitor, bms-986158, alone & with ruxolitinib or fedratinib in mf
Published 1 year ago • 82 plays • Length 2:04Download video MP4
Download video MP3
Similar videos
-
2:12
refine: phase ii study of navitoclax ruxolitinib in jak inhibitor-naive patients with mf
-
1:52
phase i dose-escalation study of the bet inhibitor incb057643 in r/r myelofibrosis
-
1:56
updated results of phase i/ii bruin study: pirtobrutinib in covalent btk inhibitor pretreated mcl
-
1:39
update on a phase i/ii study of ziftomenib in patients with r/r aml
-
2:03
preliminary results of a phase ii study of fedratinib in patients with mds/mpn and cnl
-
30:32
keystone / module 4 / session 2: health policy & systems research frameworks - 2
-
4:10
the management of prefibrotic myelofibrosis
-
3:38
mechanism of action of momelotinib to treat myelofibrosis
-
4:48
an insight into the management of cytopenias in mf
-
2:57
preliminary data from the manifest study: pelabresib in combination with ruxolitinib in mf
-
2:15
a phase i study investigating ruxolitinib and abemaciclib for primary or secondary myelofibrosis
-
1:20
the impact of early ruxolitinib treatment on os in the comfort-i and comfort-ii studies
-
1:06
fedratinib: mpn-associated myelofibrosis
-
8:03
phase ii trial of navitoclax and ruxolitinib in high-risk r/r myelofibrosis
-
1:55
the promise of pelabresib in mf and insights into the manifest-2 study
-
1:04
phase i/ii study of bosutinib in newly diagnosed & resistant/intolerant pediatric patients with cml
-
1:16
indirect comparison of the safety of momelotinib vs fedratinib in patients with myelofibrosis
-
1:58
novel myelofibrosis-associated anemia treatments in phase ii trials
-
3:38
manifest: pelabresib in combination with ruxolitinib in myelofibrosis
-
2:07
analysis of long-term exposure to momelotinib in the phase iii simplfy myelofibrosis trials
-
1:30
insights into the manifest-2 study
-
1:02
a phase ii single-arm study of obinutuzumab plus ibrutinib as frontline treatment for fl and mzl